Location: Ruminant Diseases and Immunology Research
Project Number: 5030-32000-236-007-S
Project Type: Non-Assistance Cooperative Agreement
Start Date: Apr 1, 2024
End Date: Mar 31, 2025
Objective:
To test effectiveness of MmmSC vaccines developed by ARS scientists (injectable recombinant protein vaccine), the cooperator will conduct vaccination and challenge studies in cattle, various in vitro assays, necropsy, and histochemistry. These findings could be useful to conduct large scale field trials if the vaccine is found to be safer and effective in controlling CBPP.
Approach:
The currently approved vaccine to control Contagious Bovine Pleuropneumonia (CBPP) consists of a live attenuated MmmSC vaccine (T1/44); however, based on the findings from experimental and field studies, MmmSC vaccine appeared not to fully protect cattle from outbreaks of the disease. Therefore, there is a need to develop better vaccines to control CBPP. This project will test the effectiveness of ARS vaccine against MmmSc.
Approximately 75 each of male and female Boran cattle (Bos indicus) of 2-4 years of age will be tested for MmmSC status by complement fixation test (with serum for antibodies) and nasal swabs (for live agent) before purchase. Animals will be divided into groups which will be vaccinated with the ARS product, or a variety of commercially available vaccines.
